Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Pushing The Boundaries of Efficacy in Atopic Dermatitis
Description
The presentation discusses the advancements in treating atopic dermatitis (AD), emphasizing the revolutionary impact of dupilumab, the first targeted therapy approved for AD. The speaker reflects on the long history of unmet needs in this area, particularly for patients with moderate to severe disease. Key statistics highlight that atopic dermatitis affects a significant portion of the population, especially among children and certain ethnic groups. The presentation details the pathophysiology of AD, illustrating its complexity, such as the different immune profiles across age and heritage that influence treatment responses. With a focus on developing novel therapeutics, the speaker describes recent successful trials and emerging therapies, including lebrikizumab and abrocitinib, which target multiple cytokine pathways. Additionally, safety profiles of these treatments are compared, especially concerning age-related risks. The speaker also stresses the importance of monitoring inflammation beyond the skin and highlights new methodologies like tape strip sampling to monitor treatment responses more effectively. The conclusion connects recent findings to the potential for extending therapeutic strategies from AD to related conditions like alopecia areata, indicating a promising future for personalized treatment approaches in dermatological practice.
View moreConclusions
- Atopic dermatitis is the most common inflammatory skin disease, affecting 7% of adults and 15% of children in the U.S.
- There is a large unmet need for effective long-term management of atopic dermatitis, particularly for moderate to severe cases.
- Therapeutic advancements are occurring rapidly in the field of atopic dermatitis, following initial treatments like dupilumab.
- The disease is heterogeneous, with varying immune responses and treatment requirements based on ethnicity and age.
- Inflammation in atopic dermatitis extends beyond the skin, correlating with systemic inflammatory markers and potential cardiovascular disease risk.
- Dupilumab has demonstrated significant efficacy in improving both symptoms and skin barrier function in patients with atopic dermatitis.
- New treatments such as lebrikizumab are showing promising efficacy and safety profiles, comparable to dupilumab.
- Both dupilumab and lebrikizumab target the IL-13 pathway, contributing to reduced systemic inflammation and improved clinical outcomes in patients.
- Recent studies indicate a growing pipeline of novel therapeutics targeting various pathways implicated in atopic dermatitis, including OX40/OX40L.
- Long-term treatment with tralokinumab results in a shift toward a non-lesional skin profile, highlighting the potential for symptomatic reversal of atopic dermatitis.
- Gittler JK ... and Guttman-Yassky E. J Allergy Clin Immunol Sep 2012
- Czarnowicki T, He H, Krueger JG, Guttman-Yassky E JACI 2018
- Pavel AB ... and Guttman-Yassky E. J Am Acad Dermatol. 2020; Czarnowicki T .... and Guttman-Yassky E ..: J Allergy Clin Immunol. 2015 Jul;136(1):208-11; Ungar B .... and Guttman-Yassky E et al .: J Invest Dermatol 2016; Brunner PM ... Guttman-Yassky E. Sci Reports 2017. Silverberg JI Allergy 2015 70: 1300-1308
- Noda S et al. J Allergy Clin Immunol 2015;135:324-336.
- 1. Paller AS, et al. J Allergy Clin Immunol. 2017;140(3):633-643. 2. European Medicines Agency. Dupixent. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Summary_for_the_public/human/004390/WC500236510.pdf. Accessed March 20, 2018. 3. Dupilumab [summary of product characteristics]. Paris, France: sanofi aventis groupe; 2017.
- Guttman-Yassky E et al. Lancet 2023. 2. Guttman-Yassky E, et al. J Allergy Clin Immunol. 2019;144(2):482-493. 32. Nakagawa H, et al. Poster presented at 27th EADV Congress, 12-16 Sep 2018, Paris. P0252.
- Blauvelt A, et al. AAD VMX 2021, P27697; Blauvelt A, et al. AAD VMX 2021, late-breaking research abstract. Both sponsored by LEO Pharma.